Healthcare stocks become a safe haven as investors exit tech
Executive summary: Healthcare stocks such as AbbVie, Eli Lilly and Johnson & Johnson surged to near‑record levels as investors sold technology holdings. The rotation indicates a change in risk appetite, with investors favoring defensive sectors and potentially reshaping sector‑level capital flows.
Who is involved: AbbVie, Eli Lilly, Johnson & Johnson, institutional and retail investors rotating out of tech.
Likely next: Continued inflows into healthcare if tech weakness persists; watch for earnings reports and any policy shifts affecting drug pricing.
Shares of AbbVie, Eli Lilly and Johnson & Johnson are approaching all‑time highs, signaling a renewed appetite for the biopharmaceutical sector. The move comes as market participants rotate out of technology equities, seeking defensive exposure amid uncertain growth prospects. While the shift reflects short‑term sentiment, it also highlights the relative stability healthcare offers during periods of market volatility.
Timeline
- — Healthcare stocks have become a haven for investors ditching tech (MarketWatch)
Analysis — what this means
Likely next events
- Quarterly earnings releases from major pharma firms
- FDA decisions on high‑profile drug candidates
- Congressional hearings on drug pricing
Sectors affected
- Healthcare
- Biotechnology
- Pharmaceuticals
Regulatory implications
- Ongoing scrutiny of drug pricing policies
- Possible changes to FDA approval pathways
- Impact of healthcare reform debates on reimbursement
Historical parallels
- 2022 tech‑to‑healthcare rotation during rate‑hike fears
- 2000 dot‑com bust shift to defensive stocks
- 2020 pandemic‑driven healthcare outperformance
Sources
Related cases
- Johnson & Johnson's equity portfolio reveals its top‑performing holdings among 15 stake investments
- Pharma deal volume jumps 70% to €343.5bn Jan‑Jul 2026, led by Lilly, BMS, AbbVie and GSK
- AbbVie seeks EMA approval for subcutaneous risankizumab induction in Crohn’s disease, expanding its immunology portfolio
- J&J’s $5.5 billion talc settlement removes a major overhang but leaves lingering legal risk for the healthcare conglomerate
- AbbVie’s neuroscience division is projected to generate $12.7 billion in sales this year, marking a key shift away from its Humira‑centric model
- Eli Lilly expands its weight‑loss portfolio to cover diverse patient profiles, aiming to capture broader market share